FDA Approved: NPLATE — Original Application (Amgen, Inc)

View source ↗

Summary

FDA approved NPLATE (romiplostim) under the original biologics license application for the treatment of chronic immune thrombocytopenia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Nplate (romiplostim)

Snippet

ORIG AP for NPLATE (ROMIPLOSTIM)